Literature DB >> 6184403

Identification of a membrane antigen that is distinct from the interleukin 2 receptor and that may be required for interleukin 2-driven proliferative responses.

T R Malek, R J Robb, E M Shevach.   

Abstract

During the course of studies designed to raise murine monoclonal antibodies to a guinea pig alloreactive T cell line, an IgM monoclonal antibody (5C3) was identified that completely inhibited the alloantigen and IL 2-dependent proliferative response of the immunizing colony and other alloreactive T cell colonies with different antigen specificities. Tissue distribution on the FACS demonstrated that the surface antigen defined by 5C3 was preferentially expressed on T cells activated by mitogen, alloantigen, or antigen. 5C3 was also a potent inhibitor of alloantigen- and antigen-induced T cell proliferation. In addition, 5C3 substantially inhibited the proliferative response of guinea pig Con A-induced blast cells to guinea pig IL 2-containing culture fluids and to a preparation of partially purified human IL 2 but was a poor inhibitor of mitogen-induced T cell proliferation. Blast cells obtained from the co-culture of mesenteric lymph node cells with Con A in the presence of 5C3 lacked the surface molecule defined by 5C3. The 5C3- and 5C3+ blast populations, nevertheless, absorbed equivalent amounts of IL 2, which suggested that 5C3- blasts were not deficient in the expression of IL 2 receptors. However, 5C3- blast cells failed to proliferate in response to IL 2-containing culture fluids. Furthermore, 5C3 had no inhibitory activity on either the binding or subsequent degradation of radiolabeled human IL 2 by guinea pig IL 2 receptors. These data suggest that 5C3 recognizes a component of a putative IL 2 receptor-effector complex distinct from the IL 2 receptor and that this molecule plays a critical role in the processing or generation of the growth signal IL 2 transmits to T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184403

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Interleukin-2 (IL-2) and its receptor.

Authors:  E L Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

2.  Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex.

Authors:  T R Malek; R J Robb; E M Shevach
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

3.  Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig.

Authors:  P A Steerenberg; W H De Jong; E Geerse; A Beuvink; R J Scheper; W Den Otter; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

5.  B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines.

Authors:  R Fernandez-Botran; P H Krammer; T Diamantstein; J W Uhr; E S Vitetta
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

6.  Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.

Authors:  K Welte; M Andreeff; E Platzer; K Holloway; B Y Rubin; M A Moore; R Mertelsmann
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.